GlassScriptPhysician profile
David Michael Stamper
NPI 1144948571
$4,287.77
in general payments reported to CMS, 2019-2025
23 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $1,370 · 2024: $1,770 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,977 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,977.00 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,069.58 | 2023-2025 | |
| Novo Nordisk INC | $680.70 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $424.50 | 2023-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $312.41 | 2023-2025 | Auvelity, Symbravo |
| Pfizer INC. | $285.87 | 2023-2025 | |
| Lilly USA, LLC | $207.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $173.38 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $141.96 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.31 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $129.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.30 | 2022-2024 | Fasenra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.28 | 2024-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $115.11 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.31 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $65.74 | 2023-2025 | Rexulti, Nuedexta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.04 | 2023-2024 | Gardasil 9, Gardasil, Vaxelis |
| Daiichi Sankyo INC. | $38.88 | 2024-2025 | Injectafer |
| Noven Therapeutics, LLC | $34.82 | 2024 | Xelstrym |
| Optinose US, INC. | $21.10 | 2025 | |
| Idorsia Pharmaceuticals US INC | $20.03 | 2023 | Quviviq |
| Scpharmaceuticals INC. | $19.09 | 2024 | |
| Dynavax Technologies Corporation | $18.40 | 2024 | Heplisav-B |
| Xeris Pharmaceuticals, INC. | $16.89 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stamper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.